Piceatannol, a
resveratrol metabolite, is a phenolic compound found in red wine and grapes. We investigated the effect of
piceatannol on renal
fibrosis and
histone deacetylase (HDAC) expression in a mouse model of unilateral
ureteral obstruction (UUO).
Fibrosis was established by UUO and
piceatannol was intraperitoneally injected for 2 weeks.
Piceatannol suppressed extracellular matrix (ECM)
protein deposition including
collagen type I and
fibronectin as well as
connective tissue growth factor (CTGF) and α-smooth muscle actin (α-SMA) in UUO kidneys. However, the expressions of epithelial-mesenchymal transition (EMT) marker genes, such as
N-cadherin and
E-cadherin, were not changed in the kidneys after UUO. Masson's trichrome staining and fluorescence immunostaining showed that
piceatannol administration attenuated
collagen deposition in UUO kidneys. HDAC1, HDAC4, HDAC5, HDAC6, and HDAC10
protein expression was upregulated in UUO kidneys, whereas that of HDAC8 was downregulated.
Piceatannol treatment significantly reduced HDAC4 and HDAC5
protein expression. Further,
piceatannol attenuated phosphorylation of
p38 mitogen-activated protein kinase (p38-MAPK) in UUO kidneys, but not that of
transforming growth factor beta1-Smad2/3. These results suggest that class I HDACs and class IIa/b HDACs are involved in renal
fibrosis development.
Piceatannol may be a beneficial therapeutic agent for treating renal
fibrosis via reduction of HDAC4 and HDAC5
protein expression or suppression of the p38-MAPK signaling pathway.